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Background: Participation of renal cells in the pathogenesis of staphylococcal enterotoxin B (SEB) is critical for late
cleansing and sequestration of the antigens facilitated by CD1d mediated antigen sensing and recognition. This is a
noted deviation from the typical antigen recognition process that recruits the major histocompatibility complex
class II (MHC II) molecules. The immunological importance of CD1d is underscored by its influences on the
performances of natural killer T-cells and thereby mediates the innate and adaptive immune systems.
Results: Using diffraction-based dotReady™ immunoassays, the present study showed that SEB directly and
specifically conjugated to CD1d. The specificity of the conjugation between SEB and CD1d expressed on human
renal proximal tubule epithelial cells (RPTEC) was further established by selective inhibition of CD1d prior to its
exposure to SEB. We found that SEB induced the expression of CD1d on the cell surface prompting a rapid
conjugation between them. The mRNA transcripts encoding CD1d remained elevated potentially after completing
the antigen cleansing process.
Conclusion: Molecular targets associated with the delayed pathogenic response have essential therapeutic values.
Particularly in the event of bioterrorism, the caregivers are typically able to intervene much later than the toxic
exposures. Given circumstances mandate a paradigm shift from the conventional therapeutic strategy that counts
on targeting the host markers responding to the early assault of pathogens. We demonstrated the role of CD1d in
the late stage of pathogen recognition and cleansing, and thereby underscored its clinical potential in treating
bioweaponizable antigens, such as Staphylococcal enterotoxin B (SEB).Background
SEB, a member of the exotoxin family produced by
staphylococci [1,2], is a superantigen (sAg) capable of in-
ducing toxic shock through intranasal or intravenous
portals. Transmittable via air, food and water, the SEB-
induced toxemia causes pyogenic damage that manifests
as immunological irregularities, arthritis, and auto-
immune disease cascading to multi-organ dysfunction
and lethal consequences [1,3]. Continued clinical interest* Correspondence: Rasha.Hammamieh1.civ@mail.mil
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unless otherwise stated.about staphylococcal enterotoxins (SEs) is attributed to
a general inadequacy of its effective treatment [3,4].
Many incidences alleging SEB as the chief food poison-
ing contaminant [5] and its easy adaptability to biowea-
pons [6] further justify its continued clinical relevance.
Administrations of the anti-toxin and anti-inflammatory
agents are the typical clinical strategies available nowadays
[3,7]. Conventional strategies targeting early pathogenic
markers have faced some serious deficiencies particularly
when they intervene long after the pathogenic assault [8].
This concern has been multiplied by the failure of the con-
ventional therapeutic strategy in treating septic shock [9],
which shares many patho-clinical similarities with toxic
shock [10,11]. In the advent of chemical warfare,entral . This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sault. Hence, the molecular signatures involved with the
delayed response to bioweaponizable toxins, such as SEB,
are of significant clinical interest.
Accumulating evidences suggest robust clinical efficacy
in targeting the post-assault downstream candidates re-
sponsible for SEB pathogenesis [3,12]. In recent past, the
focus of investigation for clinical targets has shifted from
blood cells to the non-lymphoid cell types derived from
kidney [13], spleen [14], lungs [15], and gut [16]. Recent
findings demonstrating the translocation of bacterial in-
fection from skin [17] to organs, such as kidney and
spleen without hematic invasion, further enhanced the
interests on such peripheral organs in this context. It
was also noted that many cell types [18,19] express atyp-
ical binding sites for SEB, which underscore the essenti-
ality of cell/tissue-specific studies. In other words, CD1d
(cluster of differentiation 1d glycoprotein) expressed on
kidney cell surface may demonstrate a very unique re-
sponse characteristics to SEB.
The critical role of the kidneys in exotoxin clearance
and sequestration [20-25] was attested by identifying the
renal excretion process as the primary route of removing
staphylococcal enterotoxin A (SEA) from plasma [26].
Supporting evidence includes the non-human primate
study reporting ~70% accumulation of SEB in the renal
proximal tubule epithelial cells (RPTECs) within 90 mi-
nutes of aerosol administration [22]. SEB introduced
through a cutaneous burn wound of rat was found tra-
versed to and localized in the kidney 6 days post-burn
[27], and a murine genomic study showed a delayed re-
sponse of renal genes after lethal SEB shock [12]. Fur-
ther investigation of the renal response in SEB
pathogenesis may help to identify an alternative avenue
for clinical intervention.
The present study is focused on CD1d for two primary
reasons. Firstly, CD1d selectively expressed in the renal
epithelial tissues are recruited for antigen sensing, recog-
nition and cleansing at the late stage of pathogenesis
[13,28-31]. Unlike a typical host-mediated antigen recog-
nition sequence, the intact sAgs are submitted to the
antigen presenting cells (APC) by CD1d, a phylogenetic
analog of major histocompatibility complex (MHC) class
I and II molecules operating as an antigen-trafficking
agent [32-34]. Secondly, CD1d controls the function of
natural killer T-cells (NKT cells); the CD1d-NKT cell-
mediated sAg recognition event rapidly triggers the
release of many cytokines, and thereby systematically in-
fluences the hosts’ adaptive and innate immune systems
[35,36].
The involvement of CD1d in pathogenesis has been in-
vestigated in the past, primarily focused on the lymphoid
cells [37-41], while the knowledge gap exists in compre-
hending the CD1d-mediated pathogenesis in kidney cellsand its role in the late stage of pathogenesis. To bridge
the knowledge gap, our study sought to understand the
renal response to SEB shock, focusing on the interaction
of SEB with CD1d in RPTECs.
Methods
Cells and reagents
Human RPTECs were purchased from Lonza (Frederick,
MD). SEB and biotinylated SEB (bt-SEB) (95% pure,
vendor defined) were purchased from Toxin Technology,
Inc. (Sarasota, FL). CD1d-(Immunoglobin) Ig recombinant
protein, which has extracellular MHC class I-like domains
of the human CD1d molecule fused with the VH regions
of mouse IgG1, was purchased from BD Biosciences (San
Jose, CA). Horse radish peroxidase (HRP)-linked anti-
mouse (H + L) horse antibody (HRP-anti-mouse) was ob-
tained from Cell Signaling Technology, Inc. (Danvers,
MA). Mouse IgG (msIgG), a polyclonal antibody purified
from pooled mouse serum by fractionation and ion-
exchange chromatography, was from Axela, Inc. (Toronto,
Ontario, Canada). Biotin-SP-AffiniPure Donkey Anti-
Rabbit IgG (H + L) antibody (bt-Dar) was from Jackson
ImmunoResearch Laboratories (West Grove, PA). 1-
Component TMB (3,3',5,5'-Tetramethylbenzidine) Membrane
Peroxidase Substrate (a precipitable form of TMB) was from
KPL, Inc. (Gaithersburg, MD). All other antibodies used in
this study were purchased from Abcam, Inc., Cambridge,
MA.
Diffraction-based dotReady™ immunoassay
The assays were performed in biosensors with avidin
surface chemistry (Axela, Inc.). All experiments were
carried out with the dotLab® System (Axela, Inc.).
Principle of dot®
The dot® (diffraction optics technology) utilizes diffrac-
tion grating to analyze real-time protein-protein interac-
tions. A capture reagent is immobilized on a specific
pattern of lines on the surface of a prism-shaped dotLab®
Sensor. The sensor surface forms the base of a 10 μL
flow cell. A series of discrete diffraction beams are gen-
erated when illuminating the underside of each assay
spot with a laser. The subsequent capture of the binding
partner alone or bound to a detector antibody increases
the average height of the surface pattern and causes an
increase in the diffraction intensity (DI) signal that is re-
corded in real-time. The DI signal is directly related to
the size and quantity of the bound complex [42,43]. The
size of the bound complex is not limited to the addition
of proteins, as previous studies [44] have shown that oxi-
dization of TMB, a precipitable form of HRP substrate,
can cause specific and localized precipitations on the
sensor surface and result in a significant increase of DI
signals.
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formance is very similar to the other industry standards
such as the BIAcore with a primary difference in their
tethered ligand characters [45]. Many studies reported
comparable performance of dot® technology in compar-
ing other platforms such as BIAcore, amperometric
assay or other methods for detecting real-time bimolecu-
lar interactions [46-48].
dotReady® assay
An avidin sensor was washed with running buffer contain-
ing PBS (0.154M NaCl, 0.01M phosphate, pH7.4) with
0.025% (v/v) Tween-20, and the surface was blocked to
minimize nonspecific binding using bovine serum albumin
(BSA) blocking buffer (5 mg/ml of BSA in running buffer)
for 5 m in a mixing mode that repeatedly reverses the flow
directions within the sensor. This mode was used in all sub-
sequent incubations unless noted otherwise. Subsequently,
the sensor was incubated with 10 μg/ml of bt-SEB for 10 m
and washed with running buffer. BSA blocking buffer was
applied and incubated for 5 m. The dimer of CD1d:Ig at 1
μg/ml was added and incubated for the next 10 m. The
sensor was washed with running buffer prior to a 5 m incu-
bation of the BSA blocking buffer. HRP-anti-mouse horse
antibody at a concentration of 1 μg/ml was added to the
sensor and incubated for 10 m. The sensor was washed
with running buffer and PBS buffer. Finally, TMB was in-
troduced and incubated for 10 m in static mode (i.e., the
flow stopped) and DI was reported (Figure 1A).Figure 1 The kinetics and specificity of the capture of CD1d with biotin
A. Kinetics of SEB-CD1d interaction: A representative real-time trace depicts th
dotReady™ system. Here, the X-axis indicates the assay duration in seconds (s)
was immobilized on the avidin sensor during a 10 m incubation. CD1d:Ig fusi
I-like domains of human CD1d fused with VH regions of mouse IgG1) (1 μg/m
second round of BSA washing, the complex was incubated with horse anti-m
another 10 m. Finally, TMB was added as the reporting agent. The shift of DI w
spikes are air gaps separating reagents. All non-labeled portions are attributed
indicated the binding of a reagent in this step. The highest ramp after TMB pr
increases with increasing concentrations of CD1d presented to bind SEB: The
namely, the presentation of biotinylated SEB to avidin sensor, followed by add
secondary protein and TMB, respectively intercepted with BSA washing. The n
TMB were plotted against the serially increasing concentrations of CD1d from
used to fit the curve, R2 = 0.9984. The positive correlation of the increased con
of the other reagents constant validated the assay specificity.The change in DI was recorded during each loading
episode. Prior to the introduction of each reagent, the
sensor was blocked with the BSA blocking buffer to es-
tablish the baseline. The delta (Δ) (the change of DI sig-
nals from the introduction of one reagent to the next
one) indicated the extent of binding during each step.
Each binding event was independent from each other
and evaluated separately. The DI signals derived from
each step of sequential addition were normalized against
the delta of bt-SEB binding (as “normalized DI”), thus
minimizing inter-sensor variations. Such ratio compari-
son is typical and has been reported previously [48,49].
The specificity of CD1d in binding SEB was evaluated
by systematically replacing bt-SEB with bt-Dar (Additional
file 1: Figure S1A) and CD1d:Ig with BSA (Additional file 2:
Figure S1B), keeping the rest of the assay protocol un-
changed. Furthermore, the efficacy of CD1d:Ig fusion pro-
tein was validated with two separate experiments. In one of
them, the Ig tag uncoupled from CD1d was presented in-
stead of CD1d:Ig fusion protein, keeping the rest of the
protocol unaltered. In the second experiment, HRP was
presented coupled with nonspecific mouse antibody, in-
stead of the CD1d-specific mouse antibody. The normalized
DIs reported from each of the scenarios were presented
along with the DI derived from the standard assay protocol
described above (Additional file 3: Figure S1C)
The assay was repeated with a range of concentrations
of CD1d:Ig fusion protein (0, 0.05, 0.1, 0.5, and 1.0 μg/ml),
keeping the rest of the assay conditions unchanged, andylated SEB (bt-SEB) with the dotReady system were characterized.
e kinetics of capturing CD1d with biotinylated SEB (bt-SEB) on the
and the Y-axis indicates measured diffractive index (DI). 10 μg/ml bt-SEB
on protein (extracellular major histocompatibility complex (MHC) class
l) was added and incubated for a 10 m post-BSA treatment. After a
ouse HRP-conjugated secondary antibody (HRP-anti-mouse; 1 μg/ml) for
ith time in seconds is presented herein. For all DI tracing, the upward
to the wash steps. Increased DI signals showing as an upward ramp
esentation suggests the successful binding of SEB and CD1d. B. Signal
assay followed the same sequential addition described in Figure 1A,
ition of CD1d:Ig fusion protein, horse anti-mouse HRP-conjugated
ormalized DI signals measured during 600 s after the introduction of
0 to 1.0 μg/ml. A sigmoidal dose–response (variable slope) function was
centration of CD1d:Ig with enhanced DI while keeping the concentration
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were reported in Figure 1B. All data recorded in dotLab®
Software were analyzed using GraphPad Prism® (GraphPad
Software, Inc., San Diego, CA).
RPTEC culture and fluorescence-based reporting
RPTECs were grown in REBM culture medium supple-
mented with a bullet kit containing hEGF, hydrocorti-
sone, epinephrine, insulin, triiodothyronine, transferrin
and GA-1000 (Lonza, MD). Cells were cultured and pas-
saged as per supplier’s protocol using recommended re-
agents. Cells at passage 5–6 were plated in chamber
slides at 1×106 cells/ml for 24 h at 37°C. SEB was added
to the cells at a concentration of 100 μg/ml and incu-
bated at 37°C for 15 m, 30 m, 1 h and 2 h. Post-
incubation, the cells were washed twice with 1× PBS.
For the CD1d reporting assays (Figure 2), the cells were
treated with mouse anti-CD1d antibody, incubated for
30 m on ice and washed with 1× PBS. Subsequently, 5 μl
of Alexa 594-conjugated goat anti-mouse antibodies in
1× PBS was added and incubated for 5 m on ice and
washed. The cells were resuspended in 1 ml of formalde-
hyde and 1× PBS mix (1:1) for 15 m at room
temperature, washed twice using 1× PBS, subsequently
resuspended in 1 ml of 1× PBS, and imaged using a
fluorescent microscope equipped with a digital camera
(Olympus Optical Company, Melville, NY). RPTECs
without SEB exposure were processed similarly and im-
aged, and Figure 2 reports surface expression of CD1d
after 1 h exposure to SEB or PBS treatment (negative
control).
For the SEB reporting assays (data not shown), the
cells were treated with rabbit anti-SEB antibody for 30
m on ice, washed with 1× PBS, and incubated on iceFigure 2 Influence of SEB on CD1d cell surface expression:
Fluorescence-based CD1d reporting: 1 x 106 cells/ml RPTECs
were exposed to 100 μg/ml SEB for 1 h, washed and then
probed using the mouse anti-CD1d antibody coupled to Alexa
594-conjugated goat anti-mouse (Red spots). This image is
designated as (+) SEB. The (−) SEB image was obtained from the cells
treated with the same method; however, SEB was replaced with PBS.
All images are at 60X magnification captured with a fluorescent
microscope equipped with a digital camera (Olympus Optical
Company). The red spots represent the CD1d expressed on the
cell surface.with FITC-conjugated goat anti-rabbit antibodies for 5
m. Subsequently, the cells were washed and resuspended
in 1 ml of formaldehyde and PBS mix (1:1). After incu-
bation at room temperature for 15 m, it was washed
with 1× PBS, resuspended again in 1× PBS and pro-
ceeded to imaging. The images were analyzed using a
fluorescent microscope equipped with a digital camera
(Olympus Optical Company). The control chamber slide
had no SEB loading.
For dual reporting, RPTECs were harvested, plated in
chamber slides and treated with SEB for increasing dura-
tions (15 m, 30 m, 1 h and 2 h), as per the protocol de-
scribed earlier. Post-treatment, the cells were incubated
on ice with mouse anti-CD1d antibody; after 30 m incu-
bation, rabbit anti-SEB antibody suspended in PBS was
added and the incubation on ice was continued for an-
other 30 m. The cells were washed twice, and the Alexa
Fluor 594-conjugated goat anti-mouse antibody and
FITC-conjugated goat anti-rabbit antibody suspended in
1x PBS were added to incubate for 5 m. Subsequently,
the cells were washed, resuspended in 1 ml of formalde-
hyde and PBS mix (1:1). After incubating at room
temperature for 15 m, it was washed with 1× PBS, resus-
pended again in 1× PBS and proceeded to imaging. The
images were analyzed using a fluorescent microscope
equipped with a digital camera (Olympus Optical
Company). Figure 3 shows the fluorescence images of
15 m, 30 m, 1 h and 2 h of SEB treatments.
Immunoblotting to report time dependent binding
efficiency of SEB to CD1d
Co-immunoprecipitation of CD1d-bound SEB was carried
out using the Universal Magnetic Co-IP kit (Active-Motif,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. Briefly, RPTECs were exposed to SEB for 1 h and 2
h as per the protocol described earlier. An aliquot of 400
ng of whole cell extract and 2 μg of mouse anti-CD1d
antibody was combined in a pre-chilled 1.5 ml tube and
incubated for 2 h at 4°C on a rolling shaker. Samples were
centrifuged for 30 s at 4000 rpm at 4°C, then 25 μl of
Protein G Magnetic Beads was added to each tube. The
mixture was incubated for 1 h at 4°C and centrifuged for
30 s at 4000 rpm at 4°C. Each tube was placed on a mag-
netic stand to pellet the beads, supernatants were dis-
carded, and the pellets were resuspended and
subsequently washed with 1× PBS. Immunoblotting was
performed according to the protocol described elsewhere
(Additional file 4: Figure S2) [50].
qPCR assay to assess CD1d expression
The protocol described earlier was followed to harvest
RPTECs and to expose them to 100 μg/ml SEB for 1 h,
2 h and 24 h. Total RNA was isolated from RPTECs in a
125 ml flask using TRIzol reagent (Invitrogen, Carlsbad,
Figure 3 Time course study of SEB binding to RPTECs: Fluorescence-based co-reporting of SEB and CD1d: 1 x 106 cells/ml RPTECs were
exposed to 100 μg/ml SEB, washed and then CD1d and SEB were sequentially reported. To report CD1d, mouse anti-CD1d antibodies
coupled to Alexa 594-conjugated goat anti-mouse antibodies were used (Red spots). To report SEB, rabbit anti-SEB antibodies coupled with FITC-
conjugated goat anti-rabbit antibodies were used (Green spots). Control: The “no SEB” treatment was similar to Figure 2 (not shown herein); SEB (15
m): SEB assault for 15 minutes; SEB (30 m): SEB assault for 30 minutes; SEB (1 h): SEB assault for one hour; and SEB (2 h): SEB assault for two hours. All
images are at 60X magnification imaged with a fluorescent microscope equipped with a digital camera (Olympus Optical Company).
Figure 4 Shift of CD1d mRNA expression with increased
duration of SEB exposure: Real-time PCR was carried out on
RNA extracted and converted to cDNA from SEB-exposed
RPTECs. 1 x 106 cells/ml RPTECs were exposed to 100 μg/ml SEB for 1
h, 2 h and 24 h (N =3). Data are expressed as fold-change compared to
the controls for each time point and represent the 2ΔΔCt (± SE). Welch’s
t-test p value cut-offs were designated by * < 0.05 and ** < 0.01.
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spectrophotometry followed by analysis with a Bioanalyzer
2100 (Agilent Technologies, Santa Clara, CA).
The primer sequences used for the amplification of
CD1d were 5'-GGGCACTCAGCCAGGGGACATCCTG
CCCAA-3' as forward and 5'-GATACAAGTTTGCACA
CCTTTGCACTTCTG-3' as reverse. The specificity of
each primer sequence was further confirmed by running
a BLAST search. Reverse transcription and real-time PCR
reactions were carried out using iScript cDNA Synthesis
Kit (Bio-Rad, Hercules, CA) and Real-time PCR kit
(Roche, Indianapolis, IN), respectively. Five technical repli-
cates of each reaction were completed in an I-Cycler ma-
chine (Bio-Rad). Each sample was also amplified using a
primer pair targeting 18S ribosomal RNA as the house-
keeping gene, whose selection for the present purpose was
instituted because of many past observations [51-53]. The
resultant cycle threshold data from each real-time PCR ex-
periment was converted to fold-change by using an estab-
lished algorithm [54]. The fold-change results obtained at
three time points were compared by Welch’s corrected
t-test p values * < 0.05 (Figure 4).
Immunological inhibition of CD1d fluorescence-based
reporting
RPTECs were harvested as per the protocol described
earlier, and 1 × 106 cells/ml loaded in chamber slides
were treated with 1 μg/ml rabbit anti-CD1d antibody (or
PBS as negative control), termed as SEB + CD1d in
Figure 5, for 30 m. Post-wash, the cells were exposed to
100 μg/ml SEB for 1 h. There was one additional set of
controls termed as inhCD1d (Figure 5) that did not
undergo the SEB treatment, but the rest of the protocol
was carried out as previously described. Post-treatment,
the cells were incubated on ice with anti-SEB rabbit anti-
body for 30 m on ice. The cells were washed twice, and
the goat anti-rabbit FITC-conjugated secondary antibodysuspended in 1× PBS was added and incubated for 5 m.
Subsequently, the cells were washed, and resuspended in
1 ml of formaldehyde and PBS mix (1:1). After incubat-
ing at room temperature for 15 m, it was washed with
1× PBS and resuspended again in 1× PBS as before. The
fluorescence intensity was estimated using the FX scan-
ner (BioRad). A “no cell” control was used as the base-
line, and their average read outs were used for
normalization purpose. (Treated – Control ± SE) (N = 5).
Welch’s corrected t-test p values * < 0.05 was used for all
statistical notations.
Results
Binding efficiency and specificity of SEB to CD1d
The dotLab® System with diffractive optics technology
(dot®) was used to systematically investigate the binding
specificity of SEB to CD1d. In this study, biotinylated
Figure 5 Inhibition of CD1d impedes SEB binding to RPTECs:
1 × 106 cells/ml RPTECs were treated with mouse anti-CD1d
antibody (1μl/ml) or PBS for 30 m; post-wash, the cells were
exposed to 100 μg/ml SEB for 1 h. Anti-SEB rabbit antibody
followed by goat anti-rabbit FITC-conjugated secondary antibody was
used for reporting purposes. A “no cell” control was used as baseline
and the average was used to normalize intensity (Treated – Control ±
SE) (N =5); Welch’s t-test p value cut-offs were designated by * < 0.05.
The first bar (designated as SEB + CD1d) shows SEB-CD1d binding in
the absence of the inhibitory anti-CD1d antibody. A significant
reduction of signal was observed in presence of the inhibitory anti-
CD1d antibody (second bar; designated as SEB + inhCD1d). Third bar
plot (inhCD1d) shows the specificity of the anti-SEB primary antibody
and the corresponding secondary antibody towards the anti-CD1d
antibody in the absence of SEB exposure.
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with avidin surface chemistry. The binding as the result
of avidin-biotin interaction was displayed as an elevated
upward ramp of DI at the end of around 500 s episode
of BSA incubation (Figure 1A). Sequential BSA washing
and the loading of CD1d:Ig to bt-SEB (each episode of
incubation lasted for approximately 500 s) did not regis-
ter the detectable increment of DI. The conjugation of
SEB and CD1d took place nonetheless, as demonstrated
by presenting an HRP-linked detector antibody (HRP-
anti-mouse) that was conjugated to the Ig domain of
CD1d:Ig duplex. Subsequently, DI was ramped as we in-
troduced TMB, a precipitating substrate of HRP.
Four negative control assays were carried out to test the
specificity of the conjugation between SEB and CD1d. In a
mock surface control, nonspecific antibody bt-Dar was
immobilized on the surface. CD1d:Ig followed by HRP-
linked anti-mouse antibody was sequentially introduced as
described earlier. TMB administration however, failed to
increase the DI signals (Additional file 1: Figure S1A)
denying the chance of nonspecific binding of CD1d in this
assay. In an analyte blank control, BSA blank instead of
CD1d:Ig was introduced on the immobilized SEB sur-
face. Following the same assay sequence, weak signal
amplification was recorded after TMB loading (Additionalfile 2: Figure S1B). Henceforth the specificity of the HRP-
linked antibodies to CD1d:Ig was established.
Furthermore, we repeated this experiment, replacing
CD1d:Ig with either (i) the Ig tag uncoupled from
CD1d or (ii) HRP linked to nonspecific mouse antibody
(HRP-1A11), which can only bind to human cardiac
troponin T (Additional file 3: Figure S1C). Presentation of
Ig-only substrate feebly increased DI while HRP-1A11
failed to increase DI after 600 s incubation.
The assay was further repeated with serially increasing
concentrations of CD1d:Ig from 0.05 μg/ml to 1.0 μg/ml
(Figure 1B), showing concurrent increment of the corre-
sponding fluorescence signals.
Longitudinal dynamics of the conjugation of SEB and
CD1d on RPTECs’ surface
The longitudinal dynamics of RPTECs’ response to SEB
exposures were evaluated by incubating the cells with
SEB for increasing durations. To examine whether SEB
treatment can affect the intracellular trafficking of
CD1d, the distribution of CD1d expression on the
RPTEC’s surface was monitored with and without SEB
treatment. Compared to the untreated cells, the 1 h SEB
treatment elevated CD1d expression on the RPTEC’s
surface as reported by the Alexa 594-based fluorescence
assay (Figure 2).
The outcome was further validated by the qPCR assay
of the expression of CD1d after increased durations of
SEB exposures. After 1 h SEB treatment, CD1d expres-
sion became significantly higher (p < 0.05) than that of
the untreated control samples. Longer durations of SEB
treatment retained the elevated level of CD1d mRNA
transcriptomic expression (Figure 4).
The longitudinal dynamics of SEB binding to RPTEC
were reported with accompanying CD1d expression on
the cell surface (Figure 3). Sequential reporting of CD1d
and SEB using antibodies with mutually exclusive bind-
ing epitopes showed co-localization of SEB and CD1d
on the cell surface. After displaying a gradual increment
until 1 h, the expression density gradually declined as re-
ported after 2 h SEB exposure (Figure 3).
The reduction of SEB concentration conjugated to
CD1d after 2 h incubation was verified with an immuno-
blotting study (Figure S2). Here, post-1 h and −2 h SEB
exposure, the CD1d protein was surface-captured and
SEB levels were reported by sequential addition of anti-
bodies with mutually exclusive capturing epitopes. The
concentration of SEB conjugated to CD1d was found di-
minished after 2 h SEB exposure.
Consequences of inhibiting CD1d of RPTECs before SEB
exposure
RPTECs were pre-treated with polyclonal anti-CD1d
antibody before regular SEB treatment. The SEB
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inhibiting CD1d from conjugating with the antigens. In
Figure 5, the first bar from the left (SEB + CD1d) dis-
played the intensity of SEB conjugated to CD1d in the
absence of the anti-CD1d antibody. A significant reduc-
tion of signal was observed in presence of the anti-CD1d
antibody (second bar plot; SEB + inhCD1d) that inhib-
ited the CD1d ability to conjugate SEB. A faint signal
was nevertheless recorded. The third bar showed a nega-
tive signal (inhCD1d), which potentially attested that the
anti-SEB primary antibody (and the corresponding sec-
ondary antibody) shared no common epitope with anti-
CD1d polyclonal antibody.
Discussion
Multiple studies reported the critical protective role
played by the kidney in excretion of SEB [20-26].
RPTECs selectively express CD1d, which play a signifi-
cant (and MHC II-independent) role in antigen sensing
and recognition process [13,29-31]. The present study
sought to elucidate the renal pathogenesis of SEB with
the primary focus on the toxin’s interaction with CD1d
expressed on RPTECs.
Time sensitive co-localization of SEB with CD1d
expressed on RPTECs’ surface (Figure 3) was found in
accordance with others’ findings [12,32,33,55]. The renal
localization of SEB began as the toxin conjugated to
CD1d; in fact, the co-localization, which began merely
15 m post-exposure possibly explained the etiology be-
hind the ‘jumpstart’ of host immunity after CD1d-NKT
cell conjugation [35].
We also showed that SEB conjugated directly to CD1d
using the dot® platform (Figure 1A), a technology
enabling us to probe the protein-ligand interaction in a
real-time format with proven success at per the other in-
dustry standards such as BIAcore [47,48]. The direct and
specific binding of renal CD1d with SEB was further
attested by the selective immunoinhibition of CD1d
(Figure 5) that inhibited SEB to bind RPTECs at all. This
information is rather important in context to the evi-
dence that showed no direct involvement of CD1d in tu-
berculosis antigen presentation [55,56] and to other
reports suggesting non-conventional sAg presenting sites
[18,19].
We paid particular attention to minimize the risk of
false positive result of dot® assay by conducting an array of
validation experiments. These included the probing of (i)
the blank capturing agents on the surface that attested the
specificity of the SEB and CD1d binding (Additional file 1:
Figure S1A). (ii) The analyte blank control for CD1d
attested the specificity of the HRP-linked antibody to
CD1d:Ig (Additional file 2: Figure S1B). (iii) The analyte
quantity control investigated the dose titration of the
CD1d amount and verified the stoichiometric dynamicsbetween CD1d and SEB (Figure 1B). (iv)The analyte tag
negative control replacing the Ig tag control of CD1d with
msIgG reconfirmed the specificity of Ig to HRP-like anti-
body (Additional file 3: Figure S1C). Finally (v) the HRP-
linked detector antibody was replaced by HRP-1A11 as a
nonspecific detector for CD1d that revalidated the same
(Additional file 3: Figure S1C). Together these assay re-
sults imparted maximum confidence on the present infer-
ence about the direct and specific conjugation of SEB to
CD1d.
Present methodology, however was not able to empir-
ically measure the affinity between SEB and CD1d. This
could be due to a weak SEB-CD1d interaction, which
was potentially unlikely in light of the past studies that
demonstrated high affinity of CD1d for glycolipids [57];
in fact, our data displaying a short duration required to
form SEB-CD1d conjugates further supports this report
[57]. As a more probable alternative, the requirement
of a signal enhancing addendum (TMB, in this case)
could be simply due to the fact that the reagents and
the experimental conditions used in vitro in dot® exper-
iments were different from what happens in the cell. A
possible role of a secondary adjunct facilitating SEB
CD1d conjugation in the cellular environment could
not be ruled out; a more comprehensive study is
required.
The fluorescence images obtained from RPTECs dis-
played the density of SEB conjugated with CD1d without
the additional help from signal amplification agents. The
result indicated that the SEB exposure prompted the ele-
vation of CD1d expression on the cell surface (Figure 2).
As shown in Figure 3, the co-localization profile of
SEB and CD1d displayed a gradual increment of their
densities up to 1 h and concluded with a subsequent de-
cline, which suggested the eventual trafficking of SEB.
Also, Figure 2 suggested that the SEB challenges
prompted CD1d expression on the cell surface after 1 h
incubation, while the immunoblotting result (Additional
file 4: Figure S2) validated the potential excretion of
SEB. The enrichment of the cell-bound SEB depleted as
the incubation period was extended to second hour. The
present study was limited by not tracking the unbound
SEB during the second hour of exposure.
Interestingly, the transcriptomic expression of CD1d
remained elevated (Figure 4), possibly long after the SEB
was sequestered. Of note, a previous study demonstrated
a long half-life of CD1d [58]. These outcomes, coupled
with Figure 2 displaying the SEB-induced the cell surface
expression of CD1d may indicate that SEB regulates
CD1d expression on RPTEC’s surface. Further investiga-
tion of CD1d in RPTECs could have major clinical inter-
est, particularly in the context of understanding a robust
system that enables facilitation of a delayed antigenic
cleansing program [59].
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pathogenesis was further validated with a fluorescence-
based assay demonstrating the sequential inhibition of
CD1d and preventing its binding to SEB (Figure 5). In
agreement, multiple studies observed diminished host
defense as a result of the targeted CD1d deficiency
[37,40,59,60]. It was, however, beyond the scope of the
present study to suggest putative SEB-induced toxemia
through CD1d-independent routes. Such possibilities,
nonetheless, have been suggested by the recruitment of
CD1d-restricted T-cells [40,41] and invariant Natural
Killer cells [15].
Conclusion
In conclusion, the present study examined the renal
pathogenesis of SEB, which revealed a potential func-
tional role for CD1d in antigen recognition, cleansing
and sequestration [12,22,26,27]. The binding specificity
of CD1d and SEB was established. A rapid conjugation
of CD1d with SEB implicated a possible high affinity be-
tween the two molecules, particularly in RPTECs. Such
prompt interaction may facilitate the rapid surge of cyto-
kines triggered by the crosstalk between CD1d and NKT
cells [35].
The display of the co-localization of SEB and CD1d at
the RPTEC’s surface and the decline of the SEB popula-
tion on the cell surface after CD1d immunoinhibition
suggested that RPTECs undertake an exclusive CD1d-
mediated antigen presentation process. The transcrip-
tomic elevation (and cell surface expression) of CD1d in
RPTECs was concurrent with SEB exposure, which
remained elevated potentially long after SEB trafficking.
Together, a feedback-controlled conjugation of SEB and
CD1d is suggested in carrying out the recognition,
cleansing and sequestration of SEB. Further investigation
is required to establish this CD1d-mediated mechanism
as a potential downstream mechanism of SEB excretion
and a prospective therapeutic target.
Additional files
Additional file 1: Figure S1A. Validation of the kinetics of SEB-CD1d
interaction: Mock surface control: nonspecific surface antibody (bt-Dar)
did not bind to CD1d: As a mock surface control for bt-SEB, nonspecific
antibody bt-Dar (identified by the dashed circle) was immobilized on the
surface. TMB loading failed to increase the DI signals, indicating that there
wasn’t nonspecific binding of CD1d to bt-Dar.
Additional file 2: Figure S1B. Validation of the kinetics of SEB-CD1d
interaction: Analyte control, BSA blank replacement of CD1d failed to emit
signal: No CD1d:Ig fusion protein was presented in the assay, instead, a
blank BSA wash was performed. The changed reagent is identified by the
dashed circle. The specificity of horse anti-mouse HRP-conjugated antibody
to CD1d:Ig fusion protein was reported with no increment of DI trace after
TMB presentation.
Additional file 3: Figure S1C. Validation of the kinetics of SEB-CD1d
interaction: Analyte tag control: Signal decreased as (a) the Ig taguncoupled from CD1d was presented: The normalized DI signal during
600 s after the introduction of TMB was plotted against the concentrations
of CD1d from 1.0 μg/ml as reported in Additional file 1: Figure S1A (red line).
A polyclonal anti-mouse antibody (msIgG, a mixture containing all subclass
of IgG including IgG1) was presented as an analyte-negative. The rest of
the assay was same as described in Additional file 1: Figure S1A. The Ig
tag without CD1d failed to signal as reported in the blue line (msIgG (a)).
The signal decreased as (b) HRP conjugated with nonspecific antibody was
presented: HRP-1A11, a HRP-linked nonspecific mouse antibody (only
capable of binding human cardiac troponin T), was employed as a HRP
detector negative control. The rest of the assay was the same as described
in Additional file 1: Figure S1A. The nonspecific mouse antibody failed to
couple with CD1d:Ig fused protein, reporting no signal as indicated in the
green line (HRP-1A11 (b)).
Additional file 4: Figure S2. Time course study of SEB binding to
RPTECs: Immunoblotting to assess SEB levels by measuring bound CD1d:
1 x 106 cells/ ml RPTECs were exposed to 100 μg/ml SEB for two time
durations, namely 1 h and 2 h; controls were not exposed to SEB. Cells
were coupled with mouse anti-CD1d antibody and immunoprecipitated
with protein G magnetic beads. Immunoblotting was completed by
presenting the conjugate to anti-SEB rabbit antibody followed by goat
anti-rabbit HRP conjugated secondary antibody.
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